SEC Tracker
Get the app

Altimmune ALT

Altimmune appoints new directors

Item 5.02 Executive or director change, Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Major
  1. Peter Greenleaf and Alex Howarth appointed as directors effective November 2, 2026.
  2. Board size increased from nine to eleven directors.
  3. Greenleaf and Howarth receive 160,000 stock options each.
  4. John Gill, Mitchell Sayare, and Dr. Klaus Schafer to retire from board in 2027.

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Altimmune files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Prothena Corp Public PRTA public float $327M, Jun 30, 2025
  2. Usana Health Sciences USNA public float $328M, Jun 27, 2025
  3. Rigel Pharmaceuticals RIGL public float $332M, Jun 30, 2025
  4. Aura Biosciences AURA public float $321M, Jun 30, 2025
  5. Amarin AMRN public float $335M, Jun 30, 2025